secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-10-13T12:35:19+00:00
Accession:  0001104659-26-115300
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

MetaVia names Sarah Browne, M.D. Chief Medical Officer; DA-1726 Phase 1 Part 3 data due Q4 2026
--------------------------------------------------------------------------------

- Sarah Browne, M.D. appointed Chief Medical Officer effective October 12, 2026, with more than 20 years in clinical development, regulatory science and clinical medicine.
- Browne was VP of Clinical Development at Altimmune, leading pemvidutide (dual GLP-1/glucagon receptor agonist) from first-in-human through Phase 2 and an FDA End-of-Phase 2 meeting.
- Earlier she was Senior Advisor for Clinical Review at the FDA's CBER and an assistant clinical investigator at NIH; she has authored 40+ peer-reviewed publications.
- CEO Hyung Heon Kim said she joins as MetaVia prepares for anticipated Q4 2026 topline data from Part 3 of the Phase 1 trial of DA-1726 at 48 mg and 64 mg doses.
- Company is also developing vanoglipel (DA-1241) for the treatment of MASH, alongside its DA-1726 cardiometabolic program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926115300/0001104659-26-115300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926115300/mtva-20261013x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-115300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer